Advance Search
LIU Qi, JIA Yunshi, SONG Wenting, LI Wuwei. Effects of Zhima Xiaotan Huoxue Recipe on no-reflow and prognosis after percutaneous coronary intervention in low-risk non-ST-elevation acute coronary syndrome patients[J]. Journal of Clinical Medicine in Practice, 2021, 25(24): 69-73. DOI: 10.7619/jcmp.20212580
Citation: LIU Qi, JIA Yunshi, SONG Wenting, LI Wuwei. Effects of Zhima Xiaotan Huoxue Recipe on no-reflow and prognosis after percutaneous coronary intervention in low-risk non-ST-elevation acute coronary syndrome patients[J]. Journal of Clinical Medicine in Practice, 2021, 25(24): 69-73. DOI: 10.7619/jcmp.20212580
shu

Effects of Zhima Xiaotan Huoxue Recipe on no-reflow and prognosis after percutaneous coronary intervention in low-risk non-ST-elevation acute coronary syndrome patients

  • Department of Cardiology, Shijiazhuang Hospital of Traditional Chinese Medicine of Hebei Province, Shijiazhuang, Hebei, 050000

More Information
  • Received Date: June 21, 2021
  • Available Online: December 15, 2021
  • Published Date: December 27, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To explore effects of Zhima Xiaotan Huoxue Recipe on no-reflow and prognosis after percutaneous coronary intervention(PCI) in low-risk non-ST-elevation acute coronary syndrome(NSTE-ACS) patients and its possible action mechanism.
      Methods  A total of 72 low-risk NSTE-ACS patients who underwent elective PCI were selected as objects and randomly divided into control group and experimental group. A total of 36 patients in the control group were given conventional treatment and nursing by western medicine, and the experimental group orally administrated Zhima Xiaotan Huoxue Decoction 7 days before the operation based on the control group. The blood flow grading (TIMI) after operation, the incidence of no-reflow phenomenon, blood flow grading of TIMI myocardial perfusion grade (TMPG), and incidence of major adverse cardiac events (MACE), left ventricular ejection fraction (LVEF) and N-terminal precursor B type natriuretic peptide (NT-proBNP) 7 days and 30 days after surgery, interleukin (IL)-2, IL-6, hypersensitive C-reactive protein (hs-CRP) and endothelial glycocalyx degradation products heparan, Syndecan-1, hyaluronic acid levels were compared.
      Results  After the intervention, the proportions of patients with TIMI 3 and TMPG 3 and postoperative LVEF levels in the experimental group were higher than those in the control group (P < 0.05); after intervention, the incidence of no-reflow, postoperative NT-proBNP, IL-2, IL-6, hs-CRP, serum heparan sulfate, Syndecan-1, and hyaluronic acid levels in the experimental group were lower than those of the control group (P < 0.01).
      Conclusion  Zhima Xiaotan Huoxue Decoction can effectively prevent the occurrence of no-reflow after the low-risk NSTE-ACS after PCI, increase myocardial blood perfusion, reduce the total incidence of MACE, inhibit inflammation, relieve vascular endothelial damage, and improve cardiac function and prognosis.
    • FullText(HTML)
    • References (15)
  • [1]
    LIM G B. Early invasive assessment of NSTE-ACS[J]. Nat Rev Cardiol, 2018, 15(11): 653. http://www.onacademic.com/detail/journal_1000040435998510_bcad.html
    [2]
    MAYER M. Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes[J]. Am J Emerg Med, 2017, 35(3): 502-507. doi: 10.1016/j.ajem.2016.12.070
    [3]
    RODRIGUEZ F, MAHAFFEY K W. Management of patients with NSTE-ACS: a comparison of the recent AHA/ACC and ESC guidelines[J]. J Am Coll Cardiol, 2016, 68(3): 313-321. doi: 10.1016/j.jacc.2016.03.599
    [4]
    杜蕊, 陈民, 李文杰. 冠状动脉粥样硬化性心脏病中医病机研究进展[J]. 现代中西医结合杂志, 2016, 25(16): 1818-1821. doi: 10.3969/j.issn.1008-8849.2016.16.039
    [5]
    中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J]. 中华心血管病杂志, 2017, 45(5): 359-376. doi: 10.3760/cma.j.issn.0253-3758.2017.05.003
    [6]
    郑筱萸. 中药新药临床研究指导原则: 试行[M]. 北京: 中国医药科技出版社, 2002: 378-379.
    [7]
    曹勤, 徐宏伟, 沙本炎, 等. 尼可地尔对NSTE-ACS患者PCI术后慢血流/无复流疗效及炎症因子的影响[J]. 武汉大学学报: 医学版, 2018, 39(4): 663-666.
    [8]
    BANGALORE S, TOKLU B, KOTWAL A, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors[J]. BMJ, 2014, 349(11): g6419-g6428. http://pubmedcentralcanada.ca/pmcc/articles/PMC4227311/
    [9]
    ARORA R R, RAI F. Antiplatelet intervention in acute coronary syndrome[J]. Am J Ther, 2009, 16(5): e29-e40. http://europepmc.org/abstract/MED/19769880
    [10]
    郑昊钏, 龙芳, 杨华, 等. 急性冠脉综合征的发病机制及治疗进展[J]. 中国药房, 2014, 25(30): 2846-2848. doi: 10.6039/j.issn.1001-0408.2014.30.24
    [11]
    姜天童. 益气活血中成药对PCI术后患者疗效的影响及龙牙楤木总皂苷对心肌细胞凋亡的作用[D]. 北京: 北京中医药大学, 2017. http://cdmd.cnki.com.cn/Article/CDMD-10026-1017183976.htm
    [12]
    庞家栋, 沈智杰, 陈铁军, 等. 丹参酮ⅡA磺酸钠注射液干预非ST段抬高型急性冠脉综合征血瘀证的临床研究[J]. 中西医结合心脑血管病杂志, 2019, 17(5): 723-726. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY201905021.htm
    [13]
    王圆圆. 益心通脉颗粒对急性冠状动脉综合征PCI后气阴两虚、痰瘀互阻型患者的临床疗效观察[D]. 南京: 南京中医药大学, 2019. https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&filename=1019075585.nh
    [14]
    倪淑宇, 王晓丽. 活血化痰宁心饮治疗急性冠脉综合征PCI术后心绞痛疗效观察[J]. 中国中医急症, 2020, 29(3): 507-509. doi: 10.3969/j.issn.1004-745X.2020.03.036
    [15]
    IKONOMIDIS I, FROGOUDAKI A, VRETTOU A R, et al. Impaired Arterial Elastic Properties and Endothelial Glycocalyx in Patients with Embolic Stroke of Undetermined Source[J]. Thromb Haemost, 2019, 119(11): 1860-1868. http://www.researchgate.net/publication/335226171_Impaired_Arterial_Elastic_Properties_and_Endothelial_Glycocalyx_in_Patients_with_Embolic_Stroke_of_Undetermined_Source
    • Related Articles

  • Related Articles

    [1]LIU Hua, ZHANG Jiangang, LI Bing, WANG Deguang, MA Zengcai, XU Zesheng. The impact of different dosages of statins in elderly patients with ST-segment elevation acute myocardial infarction undergoing percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 62-66, 72. DOI: 10.7619/jcmp.20233696
    [2]MIAO Rui, ZHANG Man, WANG Xuezhi, HAO Yafeng, LIN Li, QUAN Huijuan. Relationship of impaired glucose regulation with slow flow or no reflow during percutaneous coronary intervention in patients with ST segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 40-44, 51. DOI: 10.7619/jcmp.20234122
    [3]LOU Jiaping, MA Guodong, LIN Nanxi. Predictive value of two Rho-associated coiled-coil containing kinase for no reflow by percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 22-26. DOI: 10.7619/jcmp.20231513
    [4]ZHANG Jiangang, DAI Shipeng, LIU Hua, MA Zengcai, LIU Juan, XU Zesheng. Effect of percutaneous coronary intervention guided by intravascular ultrasound in treatment of patientswith borderline lesions of non-ST elevated acute coronary syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(15): 53-56. DOI: 10.7619/jcmp.20211247
    [5]LIN Lingdan, XU Shida, XING Haiyan. Value of serum interleukin-17 in predicting slow flow or no reflow after percutaneous coronary intervention in patients with ST-elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2021, 25(11): 93-95, 100. DOI: 10.7619/jcmp.20210482
    [6]ZHA Shuangying, FENG Liuliu, LIU Tianhua, HUANG Hongman. Effect of early application of tirofiban on body status of patients with emergency ST segment elevation myocardial infarction after percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 89-93. DOI: 10.7619/jcmp.20201404
    [7]ZHOU Yingfeng. Effect of atorvastatin on no-reflow phenomenon after emergency percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2019, (2): 40-43. DOI: 10.7619/jcmp.201902012
    [8]SANG Caidi, ZHANG Yisheng. Observation of coronary arterial injection of tirofiban on prevention of no reflow phenomenon in emergency treatment of patients with percutaneous coronary intervention and related nursing measures[J]. Journal of Clinical Medicine in Practice, 2013, (18): 60-62. DOI: 10.7619/jcmp.201318026
    [9]WANG Xiaohua, LIU Shuqin, WANG Yingli, JIN Yue. Myocardial protection of strengthening atorvastatin therapy in intervention surgery for elderly patients with non-ST-segment elevation acute coronarysyndrome[J]. Journal of Clinical Medicine in Practice, 2013, (15): 14-16. DOI: 10.7619/jcmp.201315005
    [10]ZHAO Wei, PANG Zhi-hua. Clinical study of domestic tirofiban in patients with non- ST- segment elevation acute coronary syndrome (NSTE - ACS)[J]. Journal of Clinical Medicine in Practice, 2012, (1): 42-44. DOI: 10.3969/j.issn.1672-2353.2012.01.012

Catalog

    Get Citation
    PDF
    XML
    Article views (243) PDF downloads (13) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return